London (UK) March 24th , 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. Vidac Pharma has announced the formation of “TME++,” a groundbreaking research consortium dedicated to advancing treatments for pediatric brain tumors. The initiative was launched during the first Pediatric Brain Tumor Meeting held on March 9 in Jerusalem, where leading international scientists and specialized clinicians gathered to discuss new therapeutic strategies.
The TME++ consortium was formed following recent findings on Vidac Pharma’s novel product, ALMAVID™, a Tumor Microenvironment (TME) modifier that also reactivates apoptosis (programmed cell death). A working group at the meeting, focused on the use of small molecules in brain tumor treatments, decided to collaborate on exploring ALMAVID™ in combination with traditional chemotherapy and immunotherapy.
Vidac Pharma’s CEO, Dr. Max Herzberg, presented significant progress on a new formulation of VDA1102, designed for subcutaneous administration to enhance systemic delivery and achieve therapeutic concentrations across the blood-brain barrier. This breakthrough was demonstrated in a compassionate-use study for a five-year-old child with recurrent ependymoma, a rare and aggressive brain cancer.
“Any progress in treating children with brain cancer is critical in this often-overlooked field,” said Dr. Herzberg, who will lead the consortium. “Collaborating with three university research groups and two leading hospitals brings fresh perspectives and accelerates innovation. Our new formulation not only holds promise for pediatric brain tumors but could also pave the way for treating other solid tumors. Combined with our ongoing and upcoming oncodermatology clinical trials, this is a game changer for Vidac Pharma.”
The formation of TME++ was made possible through the efforts of Dr. Iris Fried from Shaare Zedek Medical Center and Prof. Ronit Satchi-Fainaro from Tel Aviv University, who led the meeting. Additionally, Prof. Roger Packer from the University of Washington, a world-renowned leader in the field, provided key insights that helped shape the consortium’s direction.
Vidac Pharma looks forward to fostering deep collaboration within TME++ to drive transformative advancements in pediatric brain cancer treatment.
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.